- Home
- BRO vs ONC Comparison
BRO vs ONC Comparison
Compare BRO & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRO
- ONC
- Stock Information
- Founded
- BRO 1939
- ONC 2010
- Country
- BRO United States
- ONC Switzerland
- Employees
- BRO N/A
- ONC N/A
- Industry
- BRO Specialty Insurers
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- BRO Finance
- ONC Health Care
- Exchange
- BRO Nasdaq
- ONC Nasdaq
- Market Cap
- BRO 33.8B
- ONC 31.5B
- IPO Year
- BRO N/A
- ONC N/A
- Fundamental
- Price
- BRO $95.35
- ONC $321.36
- Analyst Decision
- BRO Buy
- ONC Strong Buy
- Analyst Count
- BRO 13
- ONC 9
- Target Price
- BRO $113.15
- ONC $335.78
- AVG Volume (30 Days)
- BRO 3.9M
- ONC 414.0K
- Earning Date
- BRO 07-28-2025
- ONC 08-06-2025
- Dividend Yield
- BRO 0.63%
- ONC N/A
- EPS Growth
- BRO 0.10
- ONC N/A
- EPS
- BRO 3.47
- ONC N/A
- Revenue
- BRO $4,956,000,000.00
- ONC $4,562,002,000.00
- Revenue This Year
- BRO $19.12
- ONC $865.19
- Revenue Next Year
- BRO $21.27
- ONC $21.12
- P/E Ratio
- BRO $27.44
- ONC N/A
- Revenue Growth
- BRO 11.40
- ONC 47.33
- 52 Week Low
- BRO $90.38
- ONC $170.99
- 52 Week High
- BRO $125.68
- ONC $321.69
- Technical
- Relative Strength Index (RSI)
- BRO 40.13
- ONC N/A
- Support Level
- BRO $90.38
- ONC N/A
- Resistance Level
- BRO $93.13
- ONC N/A
- Average True Range (ATR)
- BRO 1.92
- ONC 0.00
- MACD
- BRO 0.59
- ONC 0.00
- Stochastic Oscillator
- BRO 64.38
- ONC 0.00
About BRO Brown & Brown Inc.
Brown & Brown Inc is a diversified insurance agency, wholesale brokerage, insurance programs, and service. The Company markets and sells insurance products and services, in the property, casualty, and employee benefits areas. It provides customers with non-investment insurance contracts, as well as other targeted, customized risk management products and services. It has four reportable segments; the Retail segment; the Programs segment; the Wholesale Brokerage segment and; the Services segment. It generates the majority of its revenue from the Retail segment which provides insurance products and services to commercial, public and quasi-public, and Others through automobile dealer services F&I businesses. Its geographic area is U.S., U.K., the Republic of Ireland, Canada, and Others.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.